等待开盘 11-19 09:30:00 美东时间
+0.188
+1.26%
Aclaris Therapeutics has initiated a Phase 2b trial of modzatinib for moderate-to-severe lichen planus (LP), targeting oral erosive lichen planus (OLP) as the first cohort. Modzatinib, a dual ITK and JAK3 inhibitor, addresses LP at multiple immune points, potentially offering the first mechanistically complete oral therapy. The trial evaluates efficacy, safety, and tolerability across OLP, cutaneous LP, and lichen planopilaris. No FDA-approved th...
11-16 08:30
Teva Pharmaceutical Industries Ltd. has announced its first R&D Day, highlighting its growth strategy and ambitious goals to achieve $6–7 billion in innovative medicines revenue by 2030. Since launching its "Pivot to Growth" strategy in 2023, Teva has more than doubled its innovative medicines revenue, with key products like AUSTEDO®, AJOVY®, and UZEDY® expected to grow over 125% by 2026. The company is advancing its pipeline with high-value asse...
11-11 12:30
Windward Bio Group计划在美国首次公开募股(IPO)中寻求最高10亿美元的估值。该公司计划发行约1030万股股票,发行价格区间为每股16-18美元,以筹资最多1.853亿美元。
11-09 21:21
Odyssey Therapeutics reported progress in its pipeline, including additional Phase 2a data for OD-001 in ulcerative colitis and completion of IND-enabling studies for OD-002, a first-in-class SLC15A4 inhibitor. The company also appointed a chief medical officer and chief people officer. With $387 million in cash as of September 2026, Odyssey expects to fund operations into 2028. Key milestones include Phase 2b results for OD-001 and Phase 1/2a tr...
11-04 12:00
本次电话会最受关注的问题不是超预期的幅度,而是IMDELLTRA(塔拉塔单抗)在ESMO大会上公布的一线维持治疗数据。
11-04 09:26
Bolt Biotherapeutics announced its participation in two upcoming investor conferences in November 2026. Sheila Gujrathi, Bolt's Chief Strategy Officer and former CEO of Prana Therapies, will present at the Stifel 2026 Healthcare Conference on November 10 and attend the Jefferies Global Healthcare Conference in London from November 16–19. Bolt acquired Prana Therapies in October 2026 through a stock-for-stock reverse merger and a $120 million priv...
11-03 13:00
Windward Bio Group于上周五向美国证券交易委员会(SEC)提交首次公开募股(IPO)申请,拟募资至多1亿美元。
10-26 15:15
Bolt Biotherapeutics acquired Prana Therapies, gaining access to its INSPIRE platform for developing next-generation multispecific antibodies. The deal includes a $120 million private placement with potential for an additional $60 million, funding operations into 2028. PRA-216, a Phase 2 bispecific antibody targeting asthma, COPD, and atopic dermatitis, is the lead product. Prana's co-founder, Sheila Gujrathi, joins Bolt's executive team. The tra...
10-23 13:08
Kurv Tesla(TSLA)收益溢价策略主动型ETF涨11.95%,报16.3美元
10-16 15:46